The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the chances for its use in this age group in Africa. The label extension is via a type II variation – a route used when a major change is needed in the marketing authorisation for a medicine approved in Europe.

The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17. "Although the overall risk of being infected with mpox for the general EU population remains low,